All Pathways
PediatricsEmergency

Pediatric Anaphylaxis (EAACI/GA²LEN 2024)

Pediatric Anaphylaxis (EAACI/GA²LEN 2024): Suspected Pediatric Anaphylaxis → Recognize Anaphylaxis → EPINEPHRINE IM - First Line → Response to Epinephri...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Suspected Pediatric Anaphylaxis

    Acute onset multisystem allergic reaction

    1. Action

      Recognize Anaphylaxis

      Clinical criteria

      • ACUTE ONSET (minutes to hours) with:
      • • Skin/mucosal involvement (hives, swelling, pruritus, flushing)
      • + Respiratory compromise (dyspnea, wheeze, stridor, hypoxia)
      • OR + Cardiovascular (hypotension, syncope, incontinence)
      • OR exposure to known allergen with rapid onset of:
      • • Hypotension (SBP <70 + [2×age] or >30% decrease)
      1. Action

        EPINEPHRINE IM - First Line

        Give immediately - do not delay

        • DOSE: 0.01 mg/kg IM (1:1000) - max 0.5 mg
        • AUTOINJECTOR DOSES:
        • • <15 kg: 0.15 mg (Epipen Jr or equivalent)
        • • 15-25 kg: 0.15 mg or consider 0.3 mg
        • • ≥25 kg: 0.3 mg
        • SITE: Anterolateral thigh (through clothing if needed)
        • May repeat every 5-15 minutes if no response
        • Up to 3 doses usually sufficient
        1. Decision

          Response to Epinephrine?

          Reassess after 5-15 minutes

          1. Outcome

            Observation Period

            Monitor for biphasic reaction

            • Observe 4-6 hours minimum
            • High-risk (severe, refractory): observe 12-24 hours
            • Prescribe epinephrine autoinjector
            • Provide anaphylaxis action plan
            • Refer to allergist for testing
          2. Action

            Repeat Epinephrine

            Same dose IM if persistent symptoms

            • Repeat 0.01 mg/kg IM (max 0.5 mg)
            • Consider IV epinephrine if refractory:
            • • 0.01 mg/kg (1:10,000) slow IV
            • • Or infusion: 0.1-1 mcg/kg/min
            1. Action

              Adjunctive Therapies

              Secondary treatments (do NOT delay epinephrine)

              • FLUIDS: NS 20 mL/kg bolus if hypotensive
              • ANTIHISTAMINES (do not replace epi):
              • • Diphenhydramine 1-1.25 mg/kg IV/IM (max 50 mg)
              • • Cetirizine 2.5-10 mg PO if tolerated
              • CORTICOSTEROIDS (prevent biphasic):
              • • Methylprednisolone 1-2 mg/kg IV (max 125 mg)
              • • Or Prednisone 1-2 mg/kg PO (max 60 mg)
              • BRONCHODILATORS: Albuterol neb for wheeze
              1. Warning

                Refractory Anaphylaxis

                Persistent hypotension despite epinephrine

                • Continue IV fluid boluses
                • Epinephrine infusion: 0.1-1 mcg/kg/min
                • Consider glucagon if on beta-blocker:
                • • 20-30 mcg/kg (max 1 mg) IV over 5 min
                • Vasopressin may be considered
                • Prepare for intubation if airway compromise
      2. Action

        Position + Monitoring

        Supportive measures

        • Position supine with legs elevated (if tolerated)
        • If respiratory distress: allow to sit up
        • If vomiting/unconscious: recovery position
        • Apply high-flow O2
        • Monitor vitals continuously
        • Obtain IV access

Guideline Source

EAACI Anaphylaxis Guidelines 2021 + GA²LEN 2024 Consensus

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Epinephrine dosing by weight preferred over autoinjector when possible
  • Beta-blocker use may blunt epinephrine response

Applicable Regions

USEU
Version 1Next review: 2027-01-11

Frequently Asked Questions

What is the Pediatric Anaphylaxis (EAACI/GA²LEN 2024)?

The Pediatric Anaphylaxis (EAACI/GA²LEN 2024) is a emergency clinical algorithm for Pediatrics. It provides a structured decision tree to guide clinical decision-making, based on EAACI Anaphylaxis Guidelines 2021 + GA²LEN 2024 Consensus.

What guideline is the Pediatric Anaphylaxis (EAACI/GA²LEN 2024) based on?

This algorithm is based on EAACI Anaphylaxis Guidelines 2021 + GA²LEN 2024 Consensus (DOI: 10.1111/all.15032).

What are the limitations of the Pediatric Anaphylaxis (EAACI/GA²LEN 2024)?

Known limitations include: Epinephrine dosing by weight preferred over autoinjector when possible; Beta-blocker use may blunt epinephrine response. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Pediatric Anaphylaxis (EAACI/GA²LEN 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free